Pivotal
Pivotal is recorded as a service provider in 23 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 23 trials · Latest update first
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
Sponsor Puma Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Sponsor Artios Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
A Master Protocol for EG-70 in Urothelial Cancers: "A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment" BLADDER RINSE SUBSTUDY: EG-70-101 Studying the Addition of a Bladder Rinse Prior to Intravesical Administration of EG-70 in BCG-Unresponsive NMIBC Patients with CIS. IR-NMIBC SUBSTUDY: A Phase 2 Substudy of EG-70 (Detalimogene) as an Intravesical Immunoablative Treatment in Patients with Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
Sponsor Engene Inc.
- Start (EU)
- Latest update
- Estimated end
An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod® (imiquimod 50 mg/g, Gel) compared with Aldara® (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults.
Sponsor Laboratorios Ojer Pharma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin)- unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
Sponsor Associacio Per A La Recerca Oncologica
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label dose escalation study to evaluate safety, tolerability, biodistribution and efficacy of [90Y]Y-PentixaTher for the therapy of recurrent or refractory primary or isolated secondary central nervous system lymphoma
Sponsor Pentixapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
AN OPEN-LABEL PHASE 2 STUDY TO EVALUATE PT2977 FOR THE TREATMENT OF VONHIPPEL-LINDAU DISEASE-ASSOCIATED RENAL CELL CARCINOMA
Sponsor Peloton Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN)
Sponsor Grupo Espanol De Oncologia Genitourinaria-Socug
- Start (EU)
- Latest update
- Estimated end
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
Sponsor Cellcentric Limited
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE
Sponsor Asociacion Grupo Tratamiento De Tumores Digestivos
- Start (EU)
- Latest update
- Estimated end
- Not reported
A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).
Sponsor Pentixapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients with Inflammatory Lung Disease
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pivotal?
The 2026-10-09 snapshot links Pivotal to 23 distinct CTIS trials. Recorded services include Regulatory services, Clinical monitoring, Project management, Investigator recruitment, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pivotal?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Psychiatry, Gastroenterology, Gynecology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pivotal conducted?
The linked trials record locations in 19 countries, including Spain, Germany, Italy, France, Poland. These are trial locations, not confirmed office locations or countries where Pivotal delivered services.
What can this page tell me about Pivotal's trial experience?
Browse 23 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Pivotal. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pivotal S.L.